Drug Profile


Alternative Names: Rofleponide palmitate; RPL; RPNS

Latest Information Update: 07 Feb 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca Pharmaceuticals
  • Developer AstraZeneca Pharmaceuticals; Draco Lakemedel
  • Class Antiallergics; Antiasthmatics; Glucocorticoids
  • Mechanism of Action Arachidonic acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma; Inflammatory bowel diseases

Most Recent Events

  • 07 Feb 2003 Discontinued - Phase-II for Allergic rhinitis in Europe (Intranasal)
  • 07 Nov 2002 Discontinued - Preclinical for Inflammatory bowel disease in Sweden (Topical)
  • 09 Feb 2000 Discontinued-II for Asthma in Sweden (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top